Two papers landed on the same day, on two continents, and if you squint they are the same paper wearing different lab coats. One is a census. The other is a core sample. Put them side by side and you get a working blueprint for the thing we keep saying we want and rarely build: a way to measure what we manage in the diabetic foot.
Lord Kelvin’s old line still bites — if you cannot measure it, you cannot improve it. We have spent decades managing the diabetic foot with our hands, our instincts, and shockingly little structured, longitudinal data on what actually happens to the wound, the limb, and the person over time. These two studies are a deliberate attempt to fix that from opposite ends of the same telescope.
The wide field: STEADY (United States)
STEADY — the Structured Evaluation and Analysis of Diabetic Foot Ulcers registry — is the all-sky survey. Adams JR and colleagues, working through Alira Health and the Wound Care Collaborative Community (Driver VR, Snyder R, Lantis JC, Dove CR, Alper D), describe a 10-year prospective, multicenter, observational study aiming to enroll 5,000 adults with active diabetic foot ulcers across the US. It pulls from electronic case report forms, the EMR, patient-reported outcomes via a mobile app, and optional insurance claims, and it leans on an AI-enabled platform to fuse wound photography, social determinants of health, caregiver data, and dictated notes into something analyzable.
The endpoint list reads like the questions we actually argue about at the bedside: time to partial and complete closure, recurrence, infection, ischemic events, amputation, health-care utilization, quality of life, even work productivity. And in a quietly ambitious move, the authors design the dataset to be good enough to serve as a synthetic control arm for future trials. That is the wide field doing what wide fields do — capturing thousands of real patients, including the multimorbid, the underserved, and the elderly we systematically exclude from randomized trials, and giving us population-level signal we can risk-stratify.
According to PubMed: Adams JR, Lannon JN, Driver VR, et al. The STEADY diabetic foot ulcer registry: methods, insights, and future directions. Wounds. 2026;38(4):97–106. https://doi.org/10.25270/wnds/26010
The deep stare: DARE-DiaFoot (Italy)
If STEADY is the survey, the Italian DARE-DiaFoot protocol is the core sample — a deep, mechanistic stare at a small number of feet with every instrument we own. Leardini A, Dalla Paola L, Pagotto U, Berti L, Caravaggi P and colleagues, promoted by the IRCCS Istituto Ortopedico Rizzoli, lay out a no-profit, multicentre protocol that phenotypes the foot in three dimensions at once: biomechanical (multi-segment foot kinematics by stereophotogrammetry, instrumented plantar-pressure platforms, and weight-bearing CT with 3D reconstruction of bones, soft tissues, and calcifications), metabolic, and biological/biochemical (a hunt for circulating biomarkers).
Here is the part that should make every remission nerd sit up. DARE-DiaFoot compares two populations: one at moderate risk with no ulcer history (IWGDF grade 2), and one with prior ulceration that has been healed for at least six months (IWGDF grade 3). They measure both at baseline (T0) and at 12 months (T1), searching for novel biomechanical and biochemical biomarkers of ulceration risk. Whatever they call it, that second cohort is a remission cohort. They are doing exactly what we have been arguing oncology taught us to do — treat the healed foot not as cured but as a high-risk organ under surveillance, and instrument the surveillance.
According to PubMed: Leardini A, Pagotto U, Dalla Paola L, et al. Multifactorial strategies for the prevention of the risks of ulceration in patients affected by diabetic foot: a no-profit, multicentre, clinical trial protocol. BMJ Open. 2026;16(6):e112163 (NCT07021222). https://doi.org/10.1136/bmjopen-2025-112163
Why you need both lenses
This is the whole game. A registry like STEADY can tell you that a wound recurs, in whom, and at what cost — population signal at scale. A protocol like DARE-DiaFoot can tell you why — which kinematic, pressure, or biochemical fingerprint precedes the breakdown. Signal without mechanism is a weather report; mechanism without signal is a lovely hypothesis that never generalizes. Point the deep stare at the spots the survey flags, then feed the candidate biomarkers back into the registry to validate them at scale. That loop is how a field grows up.
The lineage they extend
Neither paper appeared from nowhere. They are the newest stations on a track others laid down, and it is worth cross-referencing them so we remember we are building, not starting over:
- EURODIALE — the prospective European ancestor. A consortium of 14 centres across 10 countries followed 1,232 patients with new foot ulcers and gave us the first large, standardized read on presentation, outcomes, cost, and the predictors of non-healing (age, PAD, infection, larger ulcers, the inability to stand or walk). It proved that multicentre, prospective, standardized data collection in this disease was possible. (design paper, PubMed 17344196)
- The U.S. Wound Registry / WOUNDJOURNEY — Fife CE’s long campaign to turn routine EHR documentation into a CMS-recognized Qualified Clinical Data Registry, complete with the risk-adjusted Wound Healing Index so that clinicians caring for the sickest feet are not punished for honest outcomes. This is the real-world-evidence and quality-measure scaffolding STEADY now builds on. (Wound Healing Index, PMC4900227)
- The National Diabetes Foot Care Audit (England & Wales) — the national-audit model, well over 100,000 ulcer episodes, benchmarking every service against NICE guidance on structures, processes, and outcomes. Its headline metric, alive and ulcer-free at 12 weeks, is a near-cousin of the outcome I keep pushing: ulcer-free, hospital-free, activity-rich days. (NHS England Digital, NDFA)
EURODIALE proved the concept. The USWR operationalized it inside the clinic and the payment system. The NDFA scaled it to a nation. STEADY now adds AI-grade data fusion and the synthetic-control ambition, and DARE-DiaFoot adds the mechanistic depth none of the others reached for. Stack them and the picture is coherent.
The unfinished business: a shared dialect
Here is the catch, and the call to action. These engines will only compound if they can talk to each other. A plantar-pressure map in Bologna and a wound photo in Birmingham, Alabama have to resolve to the same staging language or we are back to comparing apples and adaptive optics. This is precisely why threatened-limb classification — WIfI (Wound, Ischemia, foot Infection), built with Joe Mills — matters beyond the operating room: it is the common dialect that lets a registry, an audit, and a biomechanics lab agree on what severe means.
So the weird-ideas-with-weird-people move is obvious. Put the movement-analysis engineer, the registry data scientist, the vascular surgeon, the endocrinologist, and the patient’s phone in the same room and insist they use one vocabulary. Two studies published on the same day just handed us the census and the core sample. Our job is to make sure they are reading from the same map.
#DiabeticFoot #DiabeticFootInRemission #STEADY #DAREDiaFoot #WoundCare #LimbPreservation #AmputationPrevention #RealWorldEvidence #Registry #Biomechanics #PlantarPressure #WeightBearingCT #WIfI #MeasureWhatWeManage #ToeAndFlow #AI #WoundHealing #EURODIALE #NDFA
Leave a Reply